Finally, TD Cowen restated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Six equities research ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ ... the next-generation sequencing market. Meanwhile, TD Cowen has adjusted its price target for Illumina to ...

SAN DIEGO and CHICAGO - Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ ... about challenges in the next-generation sequencing market. Meanwhile, TD Cowen has adjusted its price target for ...

Illumina and Tempus AI have partnered to drive clinical adoption of next-generation sequencing tests beyond oncology, the companies said Tuesday. The collaborators will combine Illumina’s ...

SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $22.12. Discover ...

Illumina Inc. and Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration to accelerate clinical adoption of ...

Get Our Latest Research Report on TEM Tempus AI Stock Down 4.8 % Shares of TEM stock opened at $40.86 on Thursday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91. ...